Drugs that contain Paclitaxel
1. Abraxane patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6096331 | BRISTOL-MYERS | Methods and compositions useful for administration of chemotherapeutic agents |
Feb, 2013
(11 years ago) | |
| US6753006 | BRISTOL-MYERS | Paclitaxel-containing formulations |
Feb, 2013
(11 years ago) | |
| US5439686 | BRISTOL-MYERS | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
Feb, 2013
(11 years ago) | |
| US6506405 | BRISTOL-MYERS | Methods and formulations of cremophor-free taxanes |
Feb, 2013
(11 years ago) | |
| US6537579 | BRISTOL-MYERS | Compositions and methods for administration of pharmacologically active compounds |
Feb, 2013
(11 years ago) | |
| US6749868 | BRISTOL-MYERS | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Feb, 2013
(11 years ago) | |
| US5498421 | BRISTOL-MYERS | Composition useful for in vivo delivery of biologics and methods employing same |
Mar, 2013
(11 years ago) | |
| USRE41884 | BRISTOL-MYERS | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Aug, 2016
(7 years ago) | |
| US8853260 | BRISTOL-MYERS | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Oct, 2020
(3 years ago) | |
|
US8853260 (Pediatric) | BRISTOL-MYERS | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Apr, 2021
(3 years ago) | |
| US8314156 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US7923536 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US8138229 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
|
US8314156 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
|
US7923536 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
|
US8138229 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
| US7820788 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(6 months from now) | |
|
US7820788 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(1 year, 1 day from now) | |
| US8268348 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US7758891 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US9101543 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US8034375 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US9101543 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US7758891 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8268348 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8034375 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(2 years from now) | |
| US9393318 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
| US9597409 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
|
US9393318 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
|
US9597409 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
| US9511046 | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jan, 2034
(9 years from now) | |
|
US9511046 (Pediatric) | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jul, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
| M(M-14) | Dec 06, 2022 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| New Indication(I-658) | Oct 11, 2015 |
Market Authorisation Date: 07 January, 2005
Treatment: Method for treatment of tumors by administering paclitaxel at a dose in the range of about 30mg/meter square to about 100mg/meter square in a pharmaceutically acceptable formulation that does not cont...
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
